Escitalopram oxalate
Escitalopram Oxalate, Lexapro (escitalopram oxalate) is a small molecule pharmaceutical. Escitalopram oxalate was first approved as Lexapro on 2002-08-14. It is used to treat major depressive disorder in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| escitalopram | ANDA | 2025-02-12 |
| escitalopram oxalate | ANDA | 2025-01-20 |
| lexapro | New Drug Application | 2023-11-17 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ESCITALOPRAM OXALATE, LEXAPRO, ABBVIE | |||
| 2026-05-12 | NPP | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
699 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 22 | 60 | 77 | 130 | 106 | 379 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 25 | 65 | 80 | 129 | 97 | 378 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 15 | 48 | 53 | 80 | 60 | 248 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 5 | 6 | 12 | 15 | 14 | 49 |
| Healthy volunteers/patients | — | — | — | 24 | — | — | 4 | 7 | 35 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 5 | 6 | 7 | 18 |
| Syndrome | D013577 | — | — | 2 | 4 | 3 | 6 | 6 | 18 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | 2 | 9 | 5 | 17 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | 2 | 8 | 5 | 16 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 4 | 4 | 5 | 15 |
Show 96 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | 1 | 4 | — | 2 | 8 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | 5 | 1 | — | — | 6 |
| Hot flashes | D019584 | — | — | — | — | 1 | — | 4 | 5 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 2 | — | 1 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | 1 | 4 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | 2 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | 1 | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | — | — | 2 |
| Fatigue | D005221 | — | R53.83 | — | 1 | 1 | — | — | 2 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 2 | 2 | — | — | 2 |
Show 36 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | 6 | 7 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | 2 | — | — | 1 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | 2 | 3 |
| Ischemic stroke | D000083242 | — | — | 1 | 3 | — | — | — | 3 |
| Autism spectrum disorder | D000067877 | — | F84.0 | 1 | 1 | — | — | 1 | 3 |
| Anhedonia | D059445 | — | R45.84 | 1 | 1 | — | — | 2 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | 1 | 2 |
| Menopause | D008593 | EFO_0003922 | N95 | — | 1 | — | — | 1 | 2 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | 1 | 1 | — | — | — | 2 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | — | — | — | 1 | 3 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | 1 | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
| Respiratory insufficiency | D012131 | — | J96.9 | 2 | — | — | — | — | 2 |
| Urinary incontinence | D014549 | — | R32 | 1 | — | — | — | — | 1 |
| Stress urinary incontinence | D014550 | — | — | 1 | — | — | — | — | 1 |
| Fecal incontinence | D005242 | — | R15 | 1 | — | — | — | — | 1 |
| Enuresis | D004775 | — | R32 | 1 | — | — | — | — | 1 |
| Hepacivirus | D016174 | — | — | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 5 | 5 |
| Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 3 | 3 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 2 | 2 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 2 | 2 |
| Adolescent development | D041923 | — | — | — | — | — | — | 2 | 2 |
| Affective symptoms | D000342 | — | — | — | — | — | — | 2 | 2 |
| Perimenopause | D047648 | — | — | — | — | — | — | 1 | 1 |
| Chronic pain | D059350 | — | — | — | — | — | — | 1 | 1 |
| Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
Show 47 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Escitalopram oxalate |
| INN | — |
| Description | Escitalopram is a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram. It has a role as an antidepressant and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a conjugate base of an escitalopram(1+). It is an enantiomer of a (R)-citalopram. |
| Classification | Small molecule |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 128196-01-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200322 |
| ChEBI ID | — |
| PubChem CID | 146570 |
| DrugBank | DB01175 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,722 documents
View more details
Safety
Black-box Warning
Black-box warning for: Escitalopram, Escitalopram oxalate, Lexapro
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
43,380 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use